메뉴 건너뛰기




Volumn 1, Issue 2, 2006, Pages 171-183

Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: From biology to the bedside

Author keywords

Angiogenesis; Anti angiogenesis; Thymidine phosphorylase; Tumour progression

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; THYMIDINE PHOSPHORYLASE;

EID: 39049086320     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206777442241     Document Type: Review
Times cited : (6)

References (111)
  • 1
    • 0032529047 scopus 로고    scopus 로고
    • Thymidine phosphorylase, 2-deoxy-Dribose and angiogenesis
    • Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-Dribose and angiogenesis. Biochem J 1998; 334: 1.
    • (1998) Biochem J , vol.334 , pp. 1
    • Brown, N.S.1    Bicknell, R.2
  • 2
    • 77049164570 scopus 로고
    • The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue
    • Friedkin, M, Roberts DW. The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J Biol Chem 1954; 207: 245.
    • (1954) J Biol Chem , vol.207 , pp. 245
    • Friedkin, M.1    Roberts, D.W.2
  • 3
    • 77049163441 scopus 로고
    • The enzymatic synthesis of nucleosides. II. Thymidine and related pyrimidine nucleosides
    • Friedkin M, Roberts D. The enzymatic synthesis of nucleosides. II. Thymidine and related pyrimidine nucleosides. J Biol Chem 1954; 207: 257.
    • (1954) J Biol Chem , vol.207 , pp. 257
    • Friedkin, M.1    Roberts, D.2
  • 4
    • 0016812652 scopus 로고
    • Purification and properties of thymidine phosphorylase from Salmonella typhimurium
    • Blank JG, Hoffee PA. Purification and properties of thymidine phosphorylase from Salmonella typhimurium. Arch Biochem Biophys 1975; 168: 259.
    • (1975) Arch Biochem Biophys , vol.168 , pp. 259
    • Blank, J.G.1    Hoffee, P.A.2
  • 5
    • 0016694686 scopus 로고
    • Purification of thymidine phosphorylase from Escherichia coli and its photoinactivation in the presence of thymine, thymidine, and some halogenated analogs
    • Voytek P. Purification of thymidine phosphorylase from Escherichia coli and its photoinactivation in the presence of thymine, thymidine, and some halogenated analogs. J Biol Chem 1975; 250: 3660.
    • (1975) J Biol Chem , vol.250 , pp. 3660
    • Voytek, P.1
  • 6
    • 0018124456 scopus 로고
    • Purification of thymidine phosphorylase from human amniochorion
    • Kubilus J, Lee LD, Baden HP. Purification of thymidine phosphorylase from human amniochorion. Biophys Acta 1978; 527: 221.
    • (1978) Biophys Acta , vol.527 , pp. 221
    • Kubilus, J.1    Lee, L.D.2    Baden, H.P.3
  • 7
    • 0037930620 scopus 로고    scopus 로고
    • Thymidine phosphorylase induces angiogenesis in vivo and in vitro: An evaluation of possible mechanisms
    • Sengupta S, Sellers L, Matheson HB, Fan TP. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. Br J Pharmacol 2003; 139: 219.
    • (2003) Br J Pharmacol , vol.139 , pp. 219
    • Sengupta, S.1    Sellers, L.2    Matheson, H.B.3    Fan, T.P.4
  • 8
    • 11044235579 scopus 로고    scopus 로고
    • The role of thymidine phosphorylase, an angiogenic enzyme, in tumour progression
    • Akiyama S, Furukawa T, Sumizawa T, et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumour progression. Cancer Sci 2004; 95: 851.
    • (2004) Cancer Sci , vol.95 , pp. 851
    • Akiyama, S.1    Furukawa, T.2    Sumizawa, T.3
  • 9
    • 0035576088 scopus 로고    scopus 로고
    • Chorioallantoic membrane capillary bed: A useful target for studying angiogenesis and anti-angiogenesis in vivo
    • Ribatti D, Nico B, Vacca A, Roncali L, Burri PH, Djonov V. Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. Anat Rec 2001; 264: 317.
    • (2001) Anat Rec , vol.264 , pp. 317
    • Ribatti, D.1    Nico, B.2    Vacca, A.3    Roncali, L.4    Burri, P.H.5    Djonov, V.6
  • 10
    • 0034232194 scopus 로고    scopus 로고
    • The chick embryo chorioallantoic membrane as a model for in vivo research on antiangiogenesis
    • Ribatti D, Vacca A, Roncali L, Dammacco F. The chick embryo chorioallantoic membrane as a model for in vivo research on antiangiogenesis. Curr Pharm Biotechnol 2000; 1: 73.
    • (2000) Curr Pharm Biotechnol , vol.1 , pp. 73
    • Ribatti, D.1    Vacca, A.2    Roncali, L.3    Dammacco, F.4
  • 11
    • 0037439694 scopus 로고    scopus 로고
    • Mechanisms by which tumour cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration
    • Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL. Mechanisms by which tumour cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res 2003; 63: 527.
    • (2003) Cancer Res , vol.63 , pp. 527
    • Hotchkiss, K.A.1    Ashton, A.W.2    Klein, R.S.3    Lenzi, M.L.4    Zhu, G.H.5    Schwartz, E.L.6
  • 12
    • 12144287351 scopus 로고    scopus 로고
    • Blockage of 2-deoxy-Dribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy
    • Seeliger H, Guba M, Koehl GE, et al. Blockage of 2-deoxy-Dribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 2004; 10: 1843.
    • (2004) Clin Cancer Res , vol.10 , pp. 1843
    • Seeliger, H.1    Guba, M.2    Koehl, G.E.3
  • 13
    • 14644393663 scopus 로고    scopus 로고
    • Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment
    • Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005; 6: 158.
    • (2005) Lancet Oncol , vol.6 , pp. 158
    • Toi, M.1    Atiqur Rahman, M.2    Bando, H.3    Chow, L.W.4
  • 14
    • 0035427998 scopus 로고    scopus 로고
    • Thymidine phosphorylase: A two-face Janus in anticancer chemotherapy
    • Focher F, Spadari S. Thymidine phosphorylase: a two-face Janus in anticancer chemotherapy. Curr. Cancer Drug Targets 2001; 1: 141.
    • (2001) Curr. Cancer Drug Targets , vol.1 , pp. 141
    • Focher, F.1    Spadari, S.2
  • 15
    • 23444455766 scopus 로고
    • Angiogenic activity of enzymes
    • Haraguchi M, Miyadera K, Uemura K, et al. Angiogenic activity of enzymes. Nature 1994; 368: 198.
    • (1994) Nature , vol.368 , pp. 198
    • Haraguchi, M.1    Miyadera, K.2    Uemura, K.3
  • 16
    • 0036493984 scopus 로고    scopus 로고
    • Relation of hypoxiainducible factor-2 alpha (HIF-2 alpha) expression in tumourinfiltrative macrophages to tumour angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer
    • Ca Leek RD, Talks KL, Pezzella F, et al. Relation of hypoxiainducible factor-2 alpha (HIF-2 alpha) expression in tumourinfiltrative macrophages to tumour angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res 2002; 62: 1326.
    • (2002) Cancer Res , vol.62 , pp. 1326
    • Ca Leek, R.D.1    Talks, K.L.2    Pezzella, F.3
  • 17
    • 0040887215 scopus 로고    scopus 로고
    • Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumour vasculature induced by TNF and IFN-gamma
    • Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumour vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408.
    • (1998) Nat Med , vol.4 , pp. 408
    • Ruegg, C.1    Yilmaz, A.2    Bieler, G.3    Bamat, J.4    Chaubert, P.5    Lejeune, F.J.6
  • 18
    • 20444397436 scopus 로고    scopus 로고
    • Thymidine phosphorylase suppresses apoptosis induced by microtubuleinterfering agents
    • Jeung HC, Che XF, Haraguchi M, et al. Thymidine phosphorylase suppresses apoptosis induced by microtubuleinterfering agents. Biochem Pharmacol 2005; 70: 13.
    • (2005) Biochem Pharmacol , vol.70 , pp. 13
    • Jeung, H.C.1    Che, X.F.2    Haraguchi, M.3
  • 19
    • 1642442534 scopus 로고    scopus 로고
    • Thymidine phosphorylase and fluoropyrimidines efficacy: A Jekyll and Hyde story
    • Ciccolini J, Evrard A, Cuq P. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anti-Cancer Agent 2004; 4: 71.
    • (2004) Curr Med Chem Anti-Cancer Agent , vol.4 , pp. 71
    • Ciccolini, J.1    Evrard, A.2    Cuq, P.3
  • 20
    • 0034472785 scopus 로고    scopus 로고
    • Thymidine phosphorylase in angiogenesis and drug resistance. Homology with platelet-derived endothelial cell growth factor
    • Peters GJ, De Bruin M, Fukushima M, et al. Thymidine phosphorylase in angiogenesis and drug resistance. Homology with platelet-derived endothelial cell growth factor. Adv Exp Med Biol 2000; 486: 291.
    • (2000) Adv Exp Med Biol , vol.486 , pp. 291
    • Peters, G.J.1    de Bruin, M.2    Fukushima, M.3
  • 21
    • 0037028218 scopus 로고    scopus 로고
    • The Sp1 transcription factor contributes to the tumour necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells
    • Zhu GH, Lenzi M, Schwartz EL. The Sp1 transcription factor contributes to the tumour necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells. Oncogene 2002; 21: 8477.
    • (2002) Oncogene , vol.21 , pp. 8477
    • Zhu, G.H.1    Lenzi, M.2    Schwartz, E.L.3
  • 22
    • 0035863390 scopus 로고    scopus 로고
    • Interferon gamma-dependent induction of thymidine phosphorylase/platelet-derived endothelial growth factor through gamma-activated sequence-like element in human macrophages
    • Goto H, Kohno K, Sone S, Akiyama S, Kuwano M, Ono M. Interferon gamma-dependent induction of thymidine phosphorylase/platelet-derived endothelial growth factor through gamma-activated sequence-like element in human macrophages. Cancer Res 2001; 61: 469.
    • (2001) Cancer Res , vol.61 , pp. 469
    • Goto, H.1    Kohno, K.2    Sone, S.3    Akiyama, S.4    Kuwano, M.5    Ono, M.6
  • 23
    • 13444261932 scopus 로고    scopus 로고
    • The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: A historical review
    • Ribatti, D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 2005; 128: 303.
    • (2005) Br J Haematol , vol.128 , pp. 303
    • Ribatti, D.1
  • 24
    • 0031742541 scopus 로고    scopus 로고
    • The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation
    • Griffiths L, Stratford IJ. The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation. Int J Radiat Oncol Biol Phys 1998; 42: 877.
    • (1998) Int J Radiat Oncol Biol Phys , vol.42 , pp. 877
    • Griffiths, L.1    Stratford, I.J.2
  • 25
    • 0033692793 scopus 로고    scopus 로고
    • Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors
    • Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000; 60: 6298.
    • (2000) Cancer Res , vol.60 , pp. 6298
    • Brown, N.S.1    Jones, A.2    Fujiyama, C.3    Harris, A.L.4    Bicknell, R.5
  • 26
    • 0029837638 scopus 로고    scopus 로고
    • What is the role of thymidine phosphorylase in tumour angiogenesis
    • Folkman, J. What is the role of thymidine phosphorylase in tumour angiogenesis. Natl Cancer Inst 1996; 88: 1091.
    • (1996) Natl Cancer Inst , vol.88 , pp. 1091
    • Folkman, J.1
  • 27
    • 0028809240 scopus 로고
    • Thymidine phosphorylase is angiogenic and promotes tumour growth
    • Moghaddam A, Zhang HT, Fan TP, et al. Thymidine phosphorylase is angiogenic and promotes tumour growth. Proc Natl Acad Sci USA 1995; 92: 998.
    • (1995) Proc Natl Acad Sci USA , vol.92 , pp. 998
    • Moghaddam, A.1    Zhang, H.T.2    Fan, T.P.3
  • 28
    • 0032695102 scopus 로고    scopus 로고
    • X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts
    • Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ish H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5: 2948.
    • (1999) Clin Cancer Res , vol.5 , pp. 2948
    • Sawada, N.1    Ishikawa, T.2    Sekiguchi, F.3    Tanaka, Y.4    Ish, H.5
  • 29
    • 4243435473 scopus 로고    scopus 로고
    • Schedule-dependency of antitumour activity in combination therapy with capecitabine (Xeloda®) and docetaxel in breast cancer models
    • Fujimoto-Ouchi K, Yasuno H, Tanaka Y. Schedule-dependency of antitumour activity in combination therapy with capecitabine (Xeloda®) and docetaxel in breast cancer models. Proc Am Assoc Cancer Res 2001; 20: 463a.
    • (2001) Proc Am Assoc Cancer Res , vol.20
    • Fujimoto-Ouchi, K.1    Yasuno, H.2    Tanaka, Y.3
  • 30
    • 0032856558 scopus 로고    scopus 로고
    • Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumour models
    • Endo M, Shinbori N, Fukase Y, et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumour models. Int J Cancer 1999; 83: 127.
    • (1999) Int J Cancer , vol.83 , pp. 127
    • Endo, M.1    Shinbori, N.2    Fukase, Y.3
  • 31
    • 0037058626 scopus 로고    scopus 로고
    • Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity
    • Fukushima M, Okabe H, Takechi T, Ichikawa W, Hirayama R. Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity. Cancer Lett 2002; 187: 103.
    • (2002) Cancer Lett , vol.187 , pp. 103
    • Fukushima, M.1    Okabe, H.2    Takechi, T.3    Ichikawa, W.4    Hirayama, R.5
  • 32
    • 0003292907 scopus 로고    scopus 로고
    • Enhanced antitumour activity of Xeloda by irinotecan in nude mice
    • Hapke G, Cao S, Rustum YM. Enhanced antitumour activity of Xeloda by irinotecan in nude mice. Proc Am Assoc Cancer Res 2001; 42: 86.
    • (2001) Proc Am Assoc Cancer Res , vol.42 , pp. 86
    • Hapke, G.1    Cao, S.2    Rustum, Y.M.3
  • 33
    • 0001340091 scopus 로고    scopus 로고
    • The activity and expression of thymidine phosphorylase in human solid tumours
    • Takebayashi Y, Yamada K, Miyadera K, et al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 1996; 32A, 1227.
    • (1996) Eur J Cancer , vol.32 A , pp. 1227
    • Takebayashi, Y.1    Yamada, K.2    Miyadera, K.3
  • 34
    • 0025214992 scopus 로고
    • Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumours
    • Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K, Akiyama S. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumours. Biochim Biophys Acta 1990; 1034: 107.
    • (1990) Biochim Biophys Acta , vol.1034 , pp. 107
    • Yoshimura, A.1    Kuwazuru, Y.2    Furukawa, T.3    Yoshida, H.4    Yamada, K.5    Akiyama, S.6
  • 35
    • 0042924392 scopus 로고    scopus 로고
    • Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma
    • Morita T, Matsuzaki A, Tokue A. Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma. Oncology 2003; 65: 125.
    • (2003) Oncology , vol.65 , pp. 125
    • Morita, T.1    Matsuzaki, A.2    Tokue, A.3
  • 36
    • 0042754636 scopus 로고    scopus 로고
    • Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma
    • Ranieri G, Labriola A, Achille G, et al. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. Int J Oncol 2002; 21: 1317.
    • (2002) Int J Oncol , vol.21 , pp. 1317
    • Ranieri, G.1    Labriola, A.2    Achille, G.3
  • 37
    • 0036673313 scopus 로고    scopus 로고
    • Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia
    • Isaka S, Sawai K, Tomiie M, et al. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia. Int J Oncol 2002; 21: 281.
    • (2002) Int J Oncol , vol.21 , pp. 281
    • Isaka, S.1    Sawai, K.2    Tomiie, M.3
  • 38
    • 0036317170 scopus 로고    scopus 로고
    • Differences and relationships of thymidine phosphorylase expression in tumourassociated macrophages and cancer cells in squamous cell carcinoma of the esophagus
    • Koide N, Nishio A, Hiraguri M, et al. Differences and relationships of thymidine phosphorylase expression in tumourassociated macrophages and cancer cells in squamous cell carcinoma of the esophagus. Dis Esophagus 2002; 15: 67.
    • (2002) Dis Esophagus , vol.15 , pp. 67
    • Koide, N.1    Nishio, A.2    Hiraguri, M.3
  • 39
    • 0032783755 scopus 로고    scopus 로고
    • Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumours
    • Asgari MM, Haggerty JG, McNiff JM, Milstone LM, Schwartz PM. Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumours. Cutan Pathol 1999; 26: 287.
    • (1999) Cutan Pathol , vol.26 , pp. 287
    • Asgari, M.M.1    Haggerty, J.G.2    McNiff, J.M.3    Milstone, L.M.4    Schwartz, P.M.5
  • 40
    • 11044235579 scopus 로고    scopus 로고
    • The role of thymidine phosphorylase, an angiogenic enzyme, in tumour progression
    • Akiyama S, Furukawa T, Sumizawa T, et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumour progression. Cancer Sci 2004; 95: 851.
    • (2004) Cancer Sci , vol.95 , pp. 851
    • Akiyama, S.1    Furukawa, T.2    Sumizawa, T.3
  • 41
    • 0346780569 scopus 로고    scopus 로고
    • Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast
    • Teo NB, Shoker BS, Jarvis C, Sloane JP, Holcombe C. Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast. J Clin Pathol 2003; 56: 919.
    • (2003) J Clin Pathol , vol.56 , pp. 919
    • Teo, N.B.1    Shoker, B.S.2    Jarvis, C.3    Sloane, J.P.4    Holcombe, C.5
  • 42
    • 0037428873 scopus 로고    scopus 로고
    • Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: Implication for method to detect expression of these molecules in clinic
    • Ogura O, Kanzaki A, Bando H, Ogura T, Toi M, Takebayashi Y. Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic. Cancer Lett 2003; 190: 97.
    • (2003) Cancer Lett , vol.190 , pp. 97
    • Ogura, O.1    Kanzaki, A.2    Bando, H.3    Ogura, T.4    Toi, M.5    Takebayashi, Y.6
  • 43
    • 0032896830 scopus 로고    scopus 로고
    • Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast
    • Lee AH, Dublin EA, Bobrow LG. Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. J Pathol 1999; 187: 285.
    • (1999) J Pathol , vol.187 , pp. 285
    • Lee, A.H.1    Dublin, E.A.2    Bobrow, L.G.3
  • 44
    • 1542284704 scopus 로고    scopus 로고
    • Expression of thymidine phosphorylase by macrophages in colorectal cancer tissues
    • Zhang JM, Mizoi T, Shiiba K, Sasaki I, Matsuno S. Expression of thymidine phosphorylase by macrophages in colorectal cancer tissues. World J Gastroenterol 2004; 10: 545.
    • (2004) World J Gastroenterol , vol.10 , pp. 545
    • Zhang, J.M.1    Mizoi, T.2    Shiiba, K.3    Sasaki, I.4    Matsuno, S.5
  • 45
    • 16544375003 scopus 로고    scopus 로고
    • Localization of thymidine phosphorylase in advanced gastric and colorectal cancer
    • Kobayashi M, Okamoto K, Akimori T, et al. Localization of thymidine phosphorylase in advanced gastric and colorectal cancer. J Mol Histol 2004; 35: 69.
    • (2004) J Mol Histol , vol.35 , pp. 69
    • Kobayashi, M.1    Okamoto, K.2    Akimori, T.3
  • 46
    • 20144364091 scopus 로고    scopus 로고
    • Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoural and endothelial cells and tumour-infiltrating macrophages
    • Passantino L, Patruno R, Valerio P, et al. Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoural and endothelial cells and tumour-infiltrating macrophages. Immunopharmacol Immunotoxicol 2005; 27: 95.
    • (2005) Immunopharmacol Immunotoxicol , vol.27 , pp. 95
    • Passantino, L.1    Patruno, R.2    Valerio, P.3
  • 47
    • 15244360320 scopus 로고    scopus 로고
    • Thymidine Phosphorylase Over-Expression in Oral Squamous Carcinoma Tissue as a Potential Target of Capecitabine
    • Ranieri G, Patruno R, Fiore G, Saponaro G, Paradiso A, Grammatica L. Thymidine Phosphorylase Over-Expression in Oral Squamous Carcinoma Tissue as a Potential Target of Capecitabine. LDDD 2004; 1: 45.
    • (2004) LDDD , vol.1 , pp. 45
    • Ranieri, G.1    Patruno, R.2    Fiore, G.3    Saponaro, G.4    Paradiso, A.5    Grammatica, L.6
  • 48
    • 0038068122 scopus 로고    scopus 로고
    • Expressions of angiogenic factors in pancreatic ductal carcinoma: A correlative study with clinicopathologic parameters and patient survival
    • Kuwahara K, Sasaki T, Kuwada Y, Murakami M, Yamasaki S, Chayama K. Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 2003; 26: 344.
    • (2003) Pancreas , vol.26 , pp. 344
    • Kuwahara, K.1    Sasaki, T.2    Kuwada, Y.3    Murakami, M.4    Yamasaki, S.5    Chayama, K.6
  • 49
    • 0033391689 scopus 로고    scopus 로고
    • Expression of plateletderived endothelial cell growth factor/thymidine phosphorylase in human bladder cancer
    • Tanaka T, Yoshiki T, Arai Y, et al. Expression of plateletderived endothelial cell growth factor/thymidine phosphorylase in human bladder cancer. Jpn. J Cancer Res 1999; 90: 1344.
    • (1999) Jpn. J Cancer Res , vol.90 , pp. 1344
    • Tanaka, T.1    Yoshiki, T.2    Arai, Y.3
  • 50
    • 0041837649 scopus 로고    scopus 로고
    • Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma
    • Sato J, Sata M, Nakamura H, et al. Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma. Int J Cancer 2003; 106: 863.
    • (2003) Int J Cancer , vol.106 , pp. 863
    • Sato, J.1    Sata, M.2    Nakamura, H.3
  • 51
    • 0345491357 scopus 로고    scopus 로고
    • Dihydropyrimidine dehydrogenase in normal and malignant endometrium: Relationship with cell proliferation and thymidine phosphorylase
    • Fujiwaki R, Iida K, Nakayama K, et al. Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase. Virchows Arch 2003; 443: 672.
    • (2003) Virchows Arch , vol.443 , pp. 672
    • Fujiwaki, R.1    Iida, K.2    Nakayama, K.3
  • 52
    • 0036857261 scopus 로고    scopus 로고
    • Thymidine phosphorylase expression in tumourinfiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer
    • Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Suzuki M, Terao T. Thymidine phosphorylase expression in tumourinfiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer. Hum Pathol 2002; 33: 1105.
    • (2002) Hum Pathol , vol.33 , pp. 1105
    • Tanaka, Y.1    Kobayashi, H.2    Suzuki, M.3    Kanayama, N.4    Suzuki, M.5    Terao, T.6
  • 54
    • 0036057596 scopus 로고    scopus 로고
    • Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review
    • Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. The Oncologist 2002; 7: 288.
    • (2002) The Oncologist , vol.7 , pp. 288
    • Malet-Martino, M.1    Martino, R.2
  • 55
    • 0030477466 scopus 로고    scopus 로고
    • A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease
    • Bajetta E, Carnaghi C, Somma L, Stampino CG. A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori 1996; 82: 450.
    • (1996) Tumori , vol.82 , pp. 450
    • Bajetta, E.1    Carnaghi, C.2    Somma, L.3    Stampino, C.G.4
  • 56
    • 0032874167 scopus 로고    scopus 로고
    • A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug
    • Judson IR, Beale PJ, Trigo JM, et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs 1999; 17: 49.
    • (1999) Invest New Drugs , vol.17 , pp. 49
    • Judson, I.R.1    Beale, P.J.2    Trigo, J.M.3
  • 58
    • 0032127244 scopus 로고    scopus 로고
    • Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
    • Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274.
    • (1998) Eur J Cancer , vol.34 , pp. 1274
    • Miwa, M.1    Ura, M.2    Nishida, M.3
  • 59
    • 0034760427 scopus 로고    scopus 로고
    • Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer
    • Bell KA, Perna AG, Hsu S. Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer. J Am Acad Dermatol 2000; 45: 790.
    • (2000) J Am Acad Dermatol , vol.45 , pp. 790
    • Bell, K.A.1    Perna, A.G.2    Hsu, S.3
  • 62
    • 23844449433 scopus 로고    scopus 로고
    • Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: Retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature
    • Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16: 1289.
    • (2005) Ann Oncol , vol.16 , pp. 1289
    • Hennessy, B.T.1    Gauthier, A.M.2    Michaud, L.B.3    Hortobagyi, G.4    Valero, V.5
  • 63
    • 0033050165 scopus 로고    scopus 로고
    • Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
    • Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485.
    • (1999) J Clin Oncol , vol.17 , pp. 485
    • Blum, J.L.1    Jones, S.E.2    Buzdar, A.U.3
  • 64
    • 0033770113 scopus 로고    scopus 로고
    • Capecitabine: Preclinical pharmacology studies
    • Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000; 18: 343.
    • (2000) Invest New Drugs , vol.18 , pp. 343
    • Ishitsuka, H.1
  • 65
    • 0034079455 scopus 로고    scopus 로고
    • A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
    • Pronk LC, Vasey P, Sparreboom A, et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 2000; 83: 22.
    • (2000) Br J Cancer , vol.83 , pp. 22
    • Pronk, L.C.1    Vasey, P.2    Sparreboom, A.3
  • 66
    • 0036913666 scopus 로고    scopus 로고
    • Treatment for anthracycline-pretreated metastatic breast cancer
    • O'Shaughnessy J, Twelves C, Apro M. Treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 2002; 6: 4.
    • (2002) Oncologist , vol.6 , pp. 4
    • O'Shaughnessy, J.1    Twelves, C.2    Apro, M.3
  • 67
    • 0032807766 scopus 로고    scopus 로고
    • Rational design of new tumouractivated cytotoxic agents
    • Verweij J. Rational design of new tumouractivated cytotoxic agents. Oncology 1999; 57: 9.
    • (1999) Oncology , vol.57 , pp. 9
    • Verweij, J.1
  • 68
    • 20044364346 scopus 로고    scopus 로고
    • Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
    • Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792.
    • (2005) J Clin Oncol , vol.23 , pp. 792
    • Miller, K.D.1    Chap, L.I.2    Holmes, F.A.3
  • 69
    • 0000667912 scopus 로고    scopus 로고
    • A phase 2 trial of Xeloda (capecitabine) in advanced or metastatic pancreatic cancer
    • Cartwright T. A phase 2 trial of Xeloda (capecitabine) in advanced or metastatic pancreatic cancer Proc Am Soc Clin Oncol 2000; 19: 264a.
    • (2000) Proc Am Soc Clin Oncol , vol.19
    • Cartwright, T.1
  • 70
    • 2942638081 scopus 로고    scopus 로고
    • Active first-line therapy for patients with metastatic colorectal cancer. XELOX (capecitabine plus oxaliplatin)
    • Cassidy J, Tabernero J, Twelves C. Active first-line therapy for patients with metastatic colorectal cancer. XELOX (capecitabine plus oxaliplatin). J. Clin. Oncol 2004; 22: 2084.
    • (2004) J. Clin. Oncol , vol.22 , pp. 2084
    • Cassidy, J.1    Tabernero, J.2    Twelves, C.3
  • 71
    • 0141735508 scopus 로고    scopus 로고
    • XELOX: Mature results of a mulitnational, phase II trial of capecitabine plus oxaliplatin, an effective first-line option for patients with metastatic colorectal cancer
    • Van Cutsem E, Twelves C, Tabernero J. XELOX: mature results of a mulitnational, phase II trial of capecitabine plus oxaliplatin, an effective first-line option for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: 255.
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 255
    • van Cutsem, E.1    Twelves, C.2    Tabernero, J.3
  • 72
    • 1642535368 scopus 로고    scopus 로고
    • Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine
    • Shields AF, Zalupski MM, Marshall JL. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine. Cancer 2004; 100: 531.
    • (2004) Cancer , vol.100 , pp. 531
    • Shields, A.F.1    Zalupski, M.M.2    Marshall, J.L.3
  • 73
    • 0035987216 scopus 로고    scopus 로고
    • Capecitabine (Xeloda) in combination with oxaliplatin: A phase I, dose-escalation study in patients with advanced or metastatic solid tumours
    • Dìaz-Rubio E, Evans TR, Tabernero J. Capecitabine (Xeloda) in combination with oxaliplatin: A phase I, dose-escalation study in patients with advanced or metastatic solid tumours. Ann Oncol 2002; 13: 558-65.
    • (2002) Ann Oncol , vol.13 , pp. 558-565
    • Dìaz-Rubio, E.1    Evans, T.R.2    Tabernero, J.3
  • 74
    • 0141613762 scopus 로고    scopus 로고
    • Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: Results of an extended phase I study dagger
    • Tewes M, Schleucher N. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: Results of an extended phase I study dagger. Ann Oncol 2003; 14: 1442.
    • (2003) Ann Oncol , vol.14 , pp. 1442
    • Tewes, M.1    Schleucher, N.2
  • 75
    • 21344457969 scopus 로고    scopus 로고
    • A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
    • Rea DW, Nortier JW, Ten Bokkel Huinink WW, et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 2005; 16: 1123.
    • (2005) Ann Oncol , vol.16 , pp. 1123
    • Rea, D.W.1    Nortier, J.W.2    Ten Bokkel Huinink, W.W.3
  • 76
    • 0038744914 scopus 로고    scopus 로고
    • Dose escalation and pharmacokinetic study of capecitabine and irinotecan (CPT-11) in gastro-intestinal (GI) tumours
    • Delord JP, Pierga J, Bertheaut-Cvitkovic F. Dose escalation and pharmacokinetic study of capecitabine and irinotecan (CPT-11) in gastro-intestinal (GI) tumours. Eur J Cancer 2001; 37: 76.
    • (2001) Eur J Cancer , vol.37 , pp. 76
    • Delord, J.P.1    Pierga, J.2    Bertheaut-Cvitkovic, F.3
  • 77
    • 0346984103 scopus 로고    scopus 로고
    • Capecitabine plus irinotecan (XELIRI) in first-line metastatic colorectal cancer (MCRC): Update on a phase II trial
    • Patt YZ, Leibmann J, Diamandidis D. Capecitabine plus irinotecan (XELIRI) in first-line metastatic colorectal cancer (MCRC): Update on a phase II trial. Eur J Cancer 2003; 1: S93.
    • (2003) Eur J Cancer , vol.1
    • Patt, Y.Z.1    Leibmann, J.2    Diamandidis, D.3
  • 78
    • 4644302330 scopus 로고    scopus 로고
    • Irinotecan (CPT-11) and capecitabine (C) as first-line treatment of locally advanced or metastatic colorectal cancer (CRC)
    • Munoz A, Salut A, Escudero P. Irinotecan (CPT-11) and capecitabine (C) as first-line treatment of locally advanced or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2003; 22: 317.
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 317
    • Munoz, A.1    Salut, A.2    Escudero, P.3
  • 79
    • 0346790009 scopus 로고    scopus 로고
    • A randomized phase II trial of capecitabine (CAP) and two different schedules of irinotecan (IRI) in first-line treatment of metastatic colorectal cancer (MCC)
    • Borner MM, Dietrich D, Popescu R. A randomized phase II trial of capecitabine (CAP) and two different schedules of irinotecan (IRI) in first-line treatment of metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 2003; 22: 266.
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 266
    • Borner, M.M.1    Dietrich, D.2    Popescu, R.3
  • 80
    • 20044384354 scopus 로고    scopus 로고
    • A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity
    • Borner MM, Bernhard J, Dietrich D, et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005; 16: 282.
    • (2005) Ann Oncol , vol.16 , pp. 282
    • Borner, M.M.1    Bernhard, J.2    Dietrich, D.3
  • 81
    • 0036986164 scopus 로고    scopus 로고
    • Capecitabine and radiation therapy for advanced gastrointestinal malignancies
    • Rich T. Capecitabine and radiation therapy for advanced gastrointestinal malignancies. Oncology (Huntingt) 2002; 16: 27.
    • (2002) Oncology (Huntingt) , vol.16 , pp. 27
    • Rich, T.1
  • 82
    • 0041912759 scopus 로고    scopus 로고
    • Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer
    • Rodel C, Grabenbauer GG, Papadopoulos, T. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098.
    • (2003) J Clin Oncol , vol.21 , pp. 3098
    • Rodel, C.1    Grabenbauer, G.G.2    Papadopoulos, T.3
  • 83
    • 3042791623 scopus 로고    scopus 로고
    • Phase I/II study of preoperative radiation and capecitabine in combination with oxaliplatin in locally advanced rectal cancer: The SOCRATES study
    • Glynne-Jones R, Sebag-Montefiore D, McDonald A. Phase I/II study of preoperative radiation and capecitabine in combination with oxaliplatin in locally advanced rectal cancer: The SOCRATES study. Proc Am Soc Clin Oncol 2003; 22: 292.
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 292
    • Glynne-Jones, R.1    Sebag-Montefiore, D.2    McDonald, A.3
  • 84
    • 20144375332 scopus 로고    scopus 로고
    • Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer
    • Hofheinz RD; von Gerstenberg-Helldorf B, Wenz F, et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005; 23: 1350.
    • (2005) J Clin Oncol , vol.23 , pp. 1350
    • Hofheinz, R.D.1    von Gerstenberg-Helldorf, B.2    Wenz, F.3
  • 85
    • 32544460889 scopus 로고    scopus 로고
    • A phase I study of preoperative capecitabine, irinotecan concurrent with radiation therapy for resectable rectal cancer
    • Kennedy A, Kwok Y, Batko-Yovino S. A phase I study of preoperative capecitabine, irinotecan concurrent with radiation therapy for resectable rectal cancer. Proc Am Soc Clin Oncol 2004; 173.
    • (2004) Proc Am Soc Clin Oncol , pp. 173
    • Kennedy, A.1    Kwok, Y.2    Batko-Yovino, S.3
  • 86
    • 20244364251 scopus 로고    scopus 로고
    • Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer
    • Chun JH, Kim HK, Lee JS, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005; 28: 188.
    • (2005) Am J Clin Oncol , vol.28 , pp. 188
    • Chun, J.H.1    Kim, H.K.2    Lee, J.S.3
  • 87
    • 2342459741 scopus 로고    scopus 로고
    • A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
    • Park YH, Ryoo BY, Choi SJ, Kim HT. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2004; 90: 1329.
    • (2004) Br J Cancer , vol.90 , pp. 1329
    • Park, Y.H.1    Ryoo, B.Y.2    Choi, S.J.3    Kim, H.T.4
  • 88
    • 0035170729 scopus 로고    scopus 로고
    • Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer
    • Rauch DP, Maurer CA, Aebi S, et al. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology (Huntingt) 2001; 60: 43-8.
    • (2001) Oncology (Huntingt) , vol.60 , pp. 43-48
    • Rauch, D.P.1    Maurer, C.A.2    Aebi, S.3
  • 89
    • 10744225818 scopus 로고    scopus 로고
    • Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: An intergroup, multicenter, phase II study
    • Stathopoulos GP, Syrigos K, Polyzos A, et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 2004; 15: 224.
    • (2004) Ann Oncol , vol.15 , pp. 224
    • Stathopoulos, G.P.1    Syrigos, K.2    Polyzos, A.3
  • 90
    • 0029961618 scopus 로고    scopus 로고
    • Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
    • Rustin GJ, Nelstrop AE, McClean P. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545.
    • (1996) J Clin Oncol , vol.14 , pp. 1545
    • Rustin, G.J.1    Nelstrop, A.E.2    McClean, P.3
  • 91
    • 0002858704 scopus 로고    scopus 로고
    • A phase II trial of capecitabine (Xeloda) in relapsed ovarian cancer
    • Vasey PA, McMahon L, Paul J, Reed N, Kaye SB. A phase II trial of capecitabine (Xeloda) in relapsed ovarian cancer. Ann Oncol 2000; 11: 84a.
    • (2000) Ann Oncol , vol.11
    • Vasey, P.A.1    McMahon, L.2    Paul, J.3    Reed, N.4    Kaye, S.B.5
  • 92
    • 0346121846 scopus 로고    scopus 로고
    • A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer
    • Vasey PA, McMahon L, Paul J, Reed N, Kaye SB. A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. Br J Cancer 2003; 89: 1843.
    • (2003) Br J Cancer , vol.89 , pp. 1843
    • Vasey, P.A.1    McMahon, L.2    Paul, J.3    Reed, N.4    Kaye, S.B.5
  • 93
    • 13844298089 scopus 로고    scopus 로고
    • Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: A Gynecologic Oncology Group study
    • Garcia AA, Blessing JA, Lenz HJ, et al. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 96: 810.
    • (2005) Gynecol Oncol , vol.96 , pp. 810
    • Garcia, A.A.1    Blessing, J.A.2    Lenz, H.J.3
  • 94
    • 2342522698 scopus 로고    scopus 로고
    • Capecitabine in hormone-resistant metastatic prostatic carcinoma-a phase II trial
    • Morant R, Bernhard J, Dietrich D, et al. Capecitabine in hormone-resistant metastatic prostatic carcinoma-a phase II trial. Br J Cancer 2004; 90: 1312.
    • (2004) Br J Cancer , vol.90 , pp. 1312
    • Morant, R.1    Bernhard, J.2    Dietrich, D.3
  • 95
    • 0036142491 scopus 로고    scopus 로고
    • Oral chemotherapy with capecitabine (Xeloda) in the treatment of metastatic renal cancer failing immunotherapy
    • Wenzel C, Locker GJ, Schmidinger M, et al. Oral chemotherapy with capecitabine (Xeloda) in the treatment of metastatic renal cancer failing immunotherapy. Am J Kidney Dis 2002; 39: 48.
    • (2002) Am J Kidney Dis , vol.39 , pp. 48
    • Wenzel, C.1    Locker, G.J.2    Schmidinger, M.3
  • 96
    • 16644368159 scopus 로고    scopus 로고
    • Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: A phase II study
    • Padrik P, Leppik K, Arak A. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study. Urol Oncol 2004; 22: 387.
    • (2004) Urol Oncol , vol.22 , pp. 387
    • Padrik, P.1    Leppik, K.2    Arak, A.3
  • 97
    • 0033952360 scopus 로고    scopus 로고
    • Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy
    • Koukourakis MI, Giatromanolaki A, Fountzilas G, Sivridis E, Gatter KC, Harris AL. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res 2000; 6: 381.
    • (2000) Clin Cancer Res , vol.6 , pp. 381
    • Koukourakis, M.I.1    Giatromanolaki, A.2    Fountzilas, G.3    Sivridis, E.4    Gatter, K.C.5    Harris, A.L.6
  • 98
    • 10744232035 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of the association of capecitabinecisplatin in head and neck cancer patients
    • Pivot X, Chamorey E, Guardiola E, et al. Phase I and pharmacokinetic study of the association of capecitabinecisplatin in head and neck cancer patients. Ann Oncol 2003; 14: 1578.
    • (2003) Ann Oncol , vol.14 , pp. 1578
    • Pivot, X.1    Chamorey, E.2    Guardiola, E.3
  • 99
    • 12344270059 scopus 로고    scopus 로고
    • Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors
    • Hitt R, Jimeno A, Rodriguez-Pinilla M, et al. Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer 2004; 91: 2005.
    • (2004) Br J Cancer , vol.91 , pp. 2005
    • Hitt, R.1    Jimeno, A.2    Rodriguez-Pinilla, M.3
  • 100
    • 0036913677 scopus 로고    scopus 로고
    • Moving forward with capecitabine: A glimpse of the future
    • Biganzoli L, Martin M, Twelves C. Moving forward with capecitabine: a glimpse of the future. Oncologist 2002; 6: 29.
    • (2002) Oncologist , vol.6 , pp. 29
    • Biganzoli, L.1    Martin, M.2    Twelves, C.3
  • 101
    • 0034792770 scopus 로고    scopus 로고
    • Vision of the Future: Capecitabine
    • Twelves C. Vision of the Future: Capecitabine. Oncologist 2001; 6: 35.
    • (2001) Oncologist , vol.6 , pp. 35
    • Twelves, C.1
  • 102
    • 0037500858 scopus 로고    scopus 로고
    • Practical considerations in the use of oral fluoropyrimidines
    • Hoff PM. Practical considerations in the use of oral fluoropyrimidines. Semin Oncol 2003; 30: 88.
    • (2003) Semin Oncol , vol.30 , pp. 88
    • Hoff, P.M.1
  • 109
    • 0142135498 scopus 로고    scopus 로고
    • Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo
    • Ribatti D, Guidolin D, Conconi MT, et al. Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo. Oncogene 2003; 22: 6458.
    • (2003) Oncogene , vol.22 , pp. 6458
    • Ribatti, D.1    Guidolin, D.2    Conconi, M.T.3
  • 110
    • 16644371865 scopus 로고    scopus 로고
    • Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients
    • Ranieri G, Coviello M, Patruno R, et al. Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients. Oncol Rep 2004; 12: 817.
    • (2004) Oncol Rep , vol.12 , pp. 817
    • Ranieri, G.1    Coviello, M.2    Patruno, R.3
  • 111
    • 3242767046 scopus 로고    scopus 로고
    • Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls
    • Ranieri G, Coviello M, Chiriatti A, et al. Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls. Oncol Rep 2004; 11: 435.
    • (2004) Oncol Rep , vol.11 , pp. 435
    • Ranieri, G.1    Coviello, M.2    Chiriatti, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.